Medsger T A
University of Pittsburgh, Pennsylvania 15261, USA.
Curr Opin Rheumatol. 2000 Nov;12(6):545-8. doi: 10.1097/00002281-200011000-00012.
The determination of damage and activity in the course of a disease are important matters. Monitoring damage activity is critical in the evaluation of individual patients and in evaluating treatment efficacy in clinical trials. A disease damage (severity) scale has been published for systemic sclerosis. A number of potential cytokine and other soluble protein markers of disease activity for this disease have been proposed in recent publications, reviewed here.
在疾病过程中确定损伤和活动情况是重要的事项。监测损伤活动对于评估个体患者以及评估临床试验中的治疗效果至关重要。系统性硬化症已经发布了疾病损伤（严重程度）量表。近期出版物中提出了许多针对该疾病的潜在细胞因子和其他疾病活动的可溶性蛋白质标志物，在此进行综述。
